Table 1 Baseline characteristics of the patients with rheumatoid arthritis and spondyloarthritis
RA (n = 53) | SpA (n = 71) | ||||
|---|---|---|---|---|---|
N | n (%) or mean ± SD or median [25th; 75th percentiles] | N | n (%) or mean ± SD or median [25th; 75th percentiles] | ||
Age at conception, years | 53 | 32.7 ± 5.0 | 71 | 31.7 ± 4.2 | |
Disease duration, years | 53 | 6 [3; 12] | 70 | 5 [3; 9] | |
Current smoking | 53 | 5 (9.4) | 70 | 3/70 (4.3) | |
Current alcohol consumption | 53 | 1 (1.9) | 70 | 1/70 (1.4) | |
Body mass index, kg/m² | 32 | 24.4 ± 5.8 | 41 | 24.9 ± 4.4 | |
Nulliparity | 52 | 30/52 (57.7) | 71 | 34 (47.9) | |
Rheumatoid factor positive | 51 | 39/51 (76.5) | − | − | |
ACPA positive | 52 | 37/52 (71.2) | − | − | |
Erosion | 52 | 24/52 (46.2) | − | − | |
HLA-B27 positive | − | − | 71 | 40 (56.3) | |
SpA clinical manifestation | |||||
Axial | − | − | 70 | 36/70 (51.4) | |
Peripheral | − | − | 70 | 15/70 (21.4) | |
Both | − | − | 70 | 19/70 (27.1) | |
X-ray or MRI sacroiliitis | − | − | 71 | 44 (62.0) | |
History of corticosteroid use | 53 | 42 (79.2) | 71 | 25 (35.2) | |
History of csDMARDs use | 53 | 45 (84.9) | 71 | 26 (36.6) | |
Methotrexate | 53 | 40 (75.5) | 71 | 17 (23.9) | |
Other | 53 | 17 (32.1) | 71 | 18 (25.4) | |
History of NSAIDs use | 53 | 28 (52.8) | 71 | 50 (70.4) | |
History of bDMARDs use | 53 | 28 (52.8) | 71 | 57 (80.3) | |
Disease flare in the 12 months prior to conception | 43 | 15/43 (34.9) | 36 | 35/36 (97.2) | |
Disease activity | |||||
DAS28-CRP | 40 | 2.6 ± 1.3 | − | − | |
DAS28-CRP-3 | 40 | 2.5 ± 1.1 | − | − | |
VAS global activity patient, /10 | 48 | 2 [1; 4] | 56 | 2 [1; 6] | |
VAS global activity practitioner, /10 | 40 | 1 [0; 3] | 51 | 2 [0; 4] | |
BASDAI | − | − | 59 | 3.0 ± 2.1 | |
ASDAS-CRP | − | − | 37 | 1.9 ± 1.2 | |
CRP, mg/L | 42 | 3 [1; 10] | 50 | 3 [1; 12] | |
Tender joint count* | 48 | 0 [0; 2] | 62 | 0 [0; 0] | |
Swollen joint count* | 49 | 0 [0; 2] | 62 | 0 [0; 0] | |